Centiva Capital, LP Castle Biosciences Inc Transaction History
Centiva Capital, LP
- $4.79 Billion
- Q3 2024
A detailed history of Centiva Capital, LP transactions in Castle Biosciences Inc stock. As of the latest transaction made, Centiva Capital, LP holds 19,368 shares of CSTL stock, worth $547,533. This represents 0.01% of its overall portfolio holdings.
Number of Shares
19,368
Previous 19,273
0.49%
Holding current value
$547,533
Previous $419,000
31.74%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CSTL
# of Institutions
199Shares Held
25.9MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$86.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$51.6 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$49.4 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$40.6 Million0.02% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$35.7 Million0.61% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $743M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...